Smoking Cessation Market

DelveInsight’s ‘Smoking Cessation—Market Insights, Epidemiology, and Market Forecast–2030’ report deliver an in-depth understanding of the Smoking Cessation, historical and forecasted epidemiology as well as the Smoking Cessation market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The Smoking Cessation market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Smoking Cessation market size from 2017 to 2030. The Report also covers current Smoking Cessation treatment practice/algorithm, market drivers, market barriers, unmet medical needs, SWOT analysis to curate the best of the opportunities, and assesses the underlying potential of the market.

Geography Covered

The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2017–2030

Smoking Cessation Understanding and Treatment Algorithm

Smoking Cessation Overview

Smoking cessation is the process of discontinuing tobacco smoking. When a person smokes tobacco in cigarettes, cigars or pipes, they absorb toxins that can lead to various health problems such as diabetes, cancer, chronic obstructive pulmonary disease (COPD), heart diseases, lung diseases, etc.

The main barrier to smoking cessation is nicotine addiction. Some of the most common nicotine withdrawal symptoms smokers face when they try to quit smoking include craving for smoking, mood swings, insomnia, constipation, increased appetite, anxiety, etc.

Smoking Cessation Symptoms

Stopping smoking brings about a variety of symptoms associated with physical and psychological withdrawal. Most symptoms decrease sharply during the first few days of quitting, followed by a continued, but slower rate of decline in the second and third week of abstinence. For some people, coping with withdrawal symptoms is like “riding a roller coaster”—there may be sharp turns, slow climbs, and unexpected plunges. Most symptoms pass within 2–4 weeks after stopping.

Continued in the report…..

Smoking Cessation Treatment

The treatment of smoking includes various options such as nicotine replacement therapy (NRT), non-nicotinic pharmacological therapies, behavioral therapies, and counseling.

Varenicline (Champix) and bupropion-SR (Zyban) are approved for smoking cessation. Nortriptyline and clonidine are also used in smoking cessation as off-label medicines.

In the United States, NRT is available over the counter or by prescription as patches, gum, and lozenges, and by prescription only as a nasal spray and oral inhaler. NRT provides nicotine to reduce withdrawal symptoms, including irritability, anxiety, difficulty concentrating, dysphoria, hunger, weight gain, and sleep disturbances, which occur when a smoker stops smoking.

Non-pharmacological treatments for tobacco dependence include behavioral skills training using cognitive behavioral therapy techniques, motivational interviewing, and incentives to motivate and reinforce behavior change.

Smoking Cessation Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Smokers, Gender-specific Diagnosed Prevalent Cases of Smokers, Age-specific Diagnosed Prevalent Cases of Smokers and Total Diagnosed Prevalent Cases of Smoking Cessation in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Key Findings

The total diagnosed prevalent population of Smoking Cessation in the 7MM was 49,301,950 in 2017.
The United States showed the highest diagnosed prevalent cases of smokers, as compared to EU5, and Japan. In 2017, the number of smokers in the US was estimated to be 35,288,932.
In the US, there were 19,303,046 diagnosed prevalent cases of smokers among males and 15,985,886 diagnosed prevalent cases among females in 2017.
Out of the total 35,288,932 diagnosed prevalent cases of smokers in the US, the highest cases were observed in the age group 45–64 years (14,080,284) and the least cases were observed in 18-24 years (3,140,715) in the year 2017.
Among the European-5 countries, Germany had the highest diagnosed prevalent population of smokers with 19,305,099 cases, followed by France with 14,044,812 cases. On the other hand, the United Kingdom had the lowest diagnosed prevalent population of 7,750,777 in 2017.
Japan had 19,411,835 diagnosed prevalent cases of smokers in 2017, and out of this approximately 5,610,020 diagnosed cases of smoking cessation were estimated.

Smoking Cessation Epidemiology

The epidemiology segment also provides the Smoking Cessation epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Smoking Cessation Drug Chapters

The drug chapter segment of the Smoking Cessation report encloses the detailed analysis of Smoking Cessation current therapies, mid-phase, and late-stage pipeline drugs. It also helps to understand the Smoking Cessation clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug, and the latest news and press releases.

Smoking Cessation Marketed Drugs

Varenicline (Chantix/Champix): Pfizer

Varenicline is a medication used for smoking cessation aids. It works by blocking the pleasant effects of nicotine (from smoking) on the brain. It is used together with behavior modification and counseling support to help stop smoking. In May 2006, the US FDA approved varenicline (Chantix, Champix) for use in smoking cessation; it was the first oral non‐nicotine treatment licensed by the FDA. It was also approved in the EU and Japan for smoking cessation. Patients should be treated with Chantix for 12 weeks. For patients who have successfully stopped smoking at the end of 12 weeks, an additional course of 12 weeks of treatment with Chantix is recommended to increase the likelihood of long-term abstinence further.

Varenicline binds with high affinity and selectivity at α4β2 neuronal nicotinic acetylcholine receptors. The efficacy of Chantix in smoking cessation is believed to be the result of varenicline’s activity at the α4β2 sub-type of the nicotinic receptor where its binding produces agonist activity, while simultaneously preventing nicotine binding to these receptors.